Chronic Pain - Market Insight, Epidemiology, and Market Forecast - 2036

Chronic Pain Insights and Trends

• Chronic pain is a widespread and complex condition characterized by persistent pain lasting more than 3 to 6 months and affecting nearly one-quarter of the US population.
• Pharmacologic management of chronic pain typically progresses from over-the-counter analgesics (e.g., acetaminophen and NSAIDs) to prescription therapies such as opioids, antidepressants, anticonvulsants, and corticosteroids, depending on the severity and nature of the pain.
• As treatment advances to more potent therapies, the risk of adverse effects, dependence, drug-drug interactions, and treatment-related complications increases, necessitating individualized treatment selection, ongoing monitoring, and specialist oversight to optimize outcomes while minimizing risks.
• Chronic pain imposes a substantial burden on patients, significantly impairing quality of life and increasing the risk of functional disability, opioid misuse, suicide, and other adverse health outcomes. This burden is further compounded by psychosocial factors, including mental health disorders, stress, and social determinants, which contribute to pain persistence and poorer clinical outcomes.
• Appropriate and timely management of acute and subacute pain can reduce the risk of progression to chronic pain, thereby minimizing long-term disability and preserving quality of life. However, among patients who develop chronic pain, more than two-thirds experience moderate-to-severe symptoms. While opioids remain a mainstay of treatment for many of these patients, there is substantial interest among both patients and physicians in effective non-opioid therapeutic alternatives.
• Current treatments for chronic pain typically achieve an average pain reduction of approximately 30%, which can lead to meaningful improvements in functional capacity and quality of life. However, many patients continue to experience long-term impairments in function and overall well-being. Treatment outcomes are often enhanced when coexisting psychiatric conditions are identified and managed alongside pain.
• Drugs approved for managing pain across different indications (e.g., migraine, neuropathic pain, and osteoarthritis) include galcanezumab (EMGALITY), erenumab (AIMOVIG), pregabalin (LYRICA), triamcinolone acetonide extended-release injectable suspension (ZILRETTA), diclofenac sodium topical solution (PENNSAID), mirogabalin besylate (TARLIGE), fremanezumab (AJOVY), eptinezumab (VYEPTI), and atogepant (QULIPTA).

DelveInsight's 'Chronic Pain - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the Chronic Pain , historical and forecasted epidemiology, as well as the Chronic Pain market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Chronic Pain market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates Chronic Pain patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in Chronic Pain and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Chronic Pain Market

• Upsurge in the Geriatric population

Pain is highly prevalent among older adults, and the growing population aged >=65 years is expected to drive an increase in frailty and chronic pain-related conditions, fueling demand for effective pain management therapies. However, pain management in this population is particularly challenging due to multiple comorbidities, altered treatment responses, increased susceptibility to adverse effects, polypharmacy, and the risk of medication dependence.

• Rise in awareness for Chronic Pain

Chronic pain is a prevalent and debilitating condition that significantly impairs function and quality of life, driving increased awareness efforts by governments and healthcare organizations. Greater awareness and education among patients, clinicians, caregivers, and society can improve symptom recognition, support timely diagnosis, promote self-management, and strengthen care and support systems for those living with chronic pain.

Chronic Pain Understanding and Treatment Algorithm

Chronic Pain Overview and Diagnosis

Pain begins in receptor nerve cells located beneath the skin and within body organs. When illness, injury, or another problem occurs, these receptors send signals through nerve pathways to the spinal cord and then to the brain; pain medications act by reducing or blocking these signals before they reach the brain. Chronic pain is one of the most costly health problems in the US, contributing to increased medical expenses, lost income, reduced productivity, compensation claims, and legal costs. It includes conditions such as low back pain, a major cause of activity limitation in adults; cancer pain, common in advanced stages; arthritis, and chronic headaches like migraines, cluster, and tension headaches. Other forms include nerve-related pain, central nervous system pain, and psychogenic pain without a clear physical cause. Chronic pain persists beyond normal recovery or accompanies ongoing conditions, may be intermittent or continuous, and can significantly disrupt daily life, affecting work, physical activity, and overall quality of life. It may result from past illness or injury, ongoing disease, or sometimes arise without any identifiable cause.

Current Chronic Pain Treatment Landscape

Chronic pain affects millions and is a major public health concern due to its impact on quality of life. Effective management requires a multimodal, interprofessional approach involving physicians, nurses, pharmacists, and pain specialists. Without proper treatment, it can significantly impair well-being, making timely evaluation and care essential. Chronic pain often overlaps with anxiety disorders, and some treatments address both. Medications such as SSRIs, anxiolytics, tricyclic antidepressants, and MAOIs may help manage symptoms. Non-pharmacological approaches like cognitive-behavioral therapy (CBT), relaxation techniques (e.g., breathing exercises, muscle relaxation, exercise), and complementary therapies such as yoga, acupuncture, and massage can also improve outcomes.

Chronic Pain Unmet Needs

The section "unmet needs of Chronic Pain" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. The diagnostic challenge of chronic pain

2. Lack of access to pain care

3. Impact of chronic pain of patient's quality of life (QoL)

4. Association of chronic pain with mental illness and others.....

Chronic Pain Epidemiology

Key Findings from Chronic Pain Epidemiological Analysis and Forecast

• Chronic pain affects more than 51 million US adults and is defined as pain that persists on most days or every day for longer than three months. More than 17 million US adults experience high-impact chronic pain, a severe form that significantly restricts daily activities and work productivity.
• In chronic pain, about 30% of the diagnosed cases are of mild severity, while about 70% of the cases are diagnosed in severe state. And among the various causes of chronic pain, chronic back pain is the leading cause, with 55% of the diagnosed cases being affected by this condition.
• Chronic pain prevalence increases with age, affecting about 12% of adults aged 18-29 and rising to about 36% among those 65 and older. Women are more likely than men to experience both chronic pain (~25% vs. ~23%) and high-impact chronic pain (~10% vs. ~7%).
• In Japan in 2025, chronic back pain affected ~15,300,000 patients, making it the leading cause-specific chronic pain condition in the country.

Chronic Pain Drug Analysis & Competitive Landscape

The Chronic Pain drug chapter provides a detailed, market-focused review of emerging pipeline across Phase I-III clinical trials. It covers mechanism of action, clinical trial data, patents, collaborations, strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the Chronic Pain treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Chronic Pain market.

Marketed Therapies for Chronic Pain

Atogepant (QULIPTA/AQUIPTA): AbbVie

Atogepant is a small-molecule, selective CGRP receptor antagonist. In April 2023, the US FDA approved atogepant for the preventive treatment of migraine in adults. In August 2023 the European Commission also approved atogepant (AQUIPTA) for the prophylaxis of migraine in adults who have four or more migraine days per month.

Zavegepant (ZAVZPRET): Pfizer

Zavegepant is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist. In March 2023, the US FDA approved Pfizer's zavegepant for the acute treatment of migraine with or without aura in adults.

Fremanezumab (AJOVY): Teva Pharmaceutical

Fremanezumab is a humanized monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand and blocks it's binding to the receptor, received US FDA approval for the preventive treatment of migraine in adults in September 2018. In April 2019, the European Commission also granted marketing authorization for AJOVY for the prophylaxis of migraine in adults who have at least four migraine days per month.

Chronic Pain Pipeline Analysis

Pentosan polysulfate sodium (ZILOSUL): Paradigm Biopharmaceuticals

Pentosan polysulfate sodium (PPS) is a semi-synthetic drug manufactured from the wood chips of European beech trees. Key features of PPS activity are its anti-inflammatory and tissue regenerative properties, as well as its mild anti-thrombotic activity. In May 2022, Paradigm reported that the first subjects have been randomized and dosed in the US in the PARA_OA_002 pivotal Phase III clinical trial, evaluating injectable PPS/ZILOSUL for the treatment of pain associated with knee osteoarthritis (kOA).

This drug is currently in Phase III developmental stage. This drug has been granted a Fast Track designation by the US FDA which will facilitate its development in the US for NDA.

AMZ001: Amzell

AMZ001 is a high strength, discrete, odorless and non-invasive topical gel formulation containing 3.06% diclofenac sodium. Applied directly to the knee and designed as an FDA and EMA approved proprietary technology. This non-steroidal anti-inflammatory (NSAID) medication is intended for the treatment of pain related to knee osteoarthritis (OA). Other potential indications for AMZ001 include the management of acute pain due to minor strains, sprains, and contusions, as well as for the treatment of low back pain, which is currently treated using opioids.

Chronic Pain Key Players, Market Leaders and Emerging Companies

• AbbVie
• Pfizer
• Teva Pharmaceutical
• Mesoblast
• Sangamo Therapeutics, and others.

Chronic Pain Drug Updates

• In January 2026, Mesoblast received from the US FDA on potential filing of a BLA for its allogeneic cell therapy product rexlemestrocel-L in patients with chronic discogenic low back pain (CLBP). This follows FDA's Type B meeting review of data from Mesoblast's first randomized controlled Phase III trial (MSB-DR003) on pain reduction and relationship to decreased use or elimination of opioids for up to three years following a single rexlemestrocel-L administration.
• In December 2025, In December, the FDA granted Fast Track Designation to ST-503 for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain.
• In August 2025, Tonix Pharmaceuticals announced FDA approval of cyclobenzaprine HCl sublingual tablets (TONMYA) for the treatment of fibromyalgia, with commercial launch of the product in November 2025.

Chronic Pain Market Outlook

Chronic pain is a complex, multifactorial condition with significant implications for individuals and health systems. It is associated with long term disability, psychological distress, reduced functional capacity, and diminished quality of life. Because of its persistent and multidimensional nature, chronic pain is increasingly recognized as a condition requiring comprehensive and coordinated management.

Effective treatment relies on a patient centered, multimodal approach that integrates pharmacological, non-pharmacological, and interventional strategies. Pharmacological management remains central, especially in moderate to severe cases, using a stepwise approach from non-opioid analgesics to opioids when appropriate and carefully monitored. Interventional techniques such as nerve blocks, epidural injections, and radiofrequency procedures may be used to target pain sources directly, reduce symptom burden, and limit reliance on systemic medications.

Non pharmacological interventions are equally important, addressing functional and psychological aspects of pain. Physical and occupational therapy focus on exercise, mobility, and activity adaptation, while psychological approaches such as cognitive behavioral therapy help manage emotional and cognitive responses to pain. Complementary methods including mindfulness, acupuncture, and massage may further support symptom control when used alongside conventional care.

Optimal outcomes depend on coordinated interprofessional collaboration among primary care providers, pain specialists, nurses, pharmacists, therapists, and mental health professionals. This integrated model enables individualized care, ongoing evaluation, and adjustment of treatment, with the goal of reducing pain, improving function, and enhancing quality of life.

• During the forecast period (2026-2036), pipeline candidates such as ZILOSUL and AMZ001, others are expected to drive the growth of chronic pain market size.
• TONMYA captured sales of USD 1.2 million from November to December 2025, with more than 1,500 prescribers having prescribed TONMYA to patients.
• Galcanezumab patent in the US and Europe is set to expire in 2033.
• Over the past five years, significant advances have been made in therapies targeting the CGRP pathway, leading to the approval of multiple monoclonal antibodies and small-molecule antagonists for both the prevention and acute treatment of migraine.
• Despite advances in multimodal pharmacologic treatment, many patients achieve only partial and transient pain relief because existing therapies primarily address symptoms rather than the root biological drivers of chronic pain.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Chronic Pain (2022-2036 Forecast)

The treatment landscape of Chronic Pain remains largely focused on symptom management and functional improvement; however, emerging therapies are increasingly targeting the underlying degenerative processes of the intervertebral disc.

ZILOSUL belongs to the emerging class of NGF pathway modulators, offering a mechanism-driven approach to osteoarthritis pain management by inhibiting NGF production in the knee joint. NGF plays a central role in peripheral sensitization and nociceptor activation, contributing to heightened pain perception in OA. By targeting this upstream mediator, ZILOSUL differs from conventional therapies like NSAIDs or opioids that primarily address symptoms, positioning it as a more targeted pain-modulating strategy. This approach may benefit patients with inadequately controlled moderate-to-severe pain, although class-related safety considerations, particularly regarding joint integrity, remain important in its clinical evaluation.

TONMYA represents a centrally acting therapeutic approach within the class of neuromodulatory agents, designed to improve sleep quality as a means of alleviating chronic pain. It is a sublingual, low-dose formulation of cyclobenzaprine that primarily targets central nervous system pathways involved in sleep regulation, particularly by reducing hyperarousal and improving restorative sleep architecture. Given the strong bidirectional relationship between poor sleep and chronic pain conditions such as fibromyalgia, TONMYA's mechanism focuses on indirectly modulating pain by addressing underlying sleep disturbances. This differentiates it from traditional analgesics, positioning it as an adjunctive therapy aimed at improving overall symptom burden, functional outcomes, and patient quality of life.

Chronic Pain Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the Chronic Pain drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

Detailed insights of emerging therapies' drug uptake is included in the report...

Market Access and Reimbursement of Approved therapies in Chronic Pain

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

NOTE: Further Details are provided in the final report....

Chronic Pain Therapies Price Scenario & Trends

Pricing and analogue assessment of Chronic Pain therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Chronic Pain

To keep up with Chronic Pain market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the Chronic Pain emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in Chronic Pain , including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights at country level. Centers such as the Princeton University, Caltech University, and Harvard, etc. were contacted. Their opinion helps understand and validate current and emerging Chronic Pain therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in Chronic Pain.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Chronic Pain, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed.

In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of Chronic Pain, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Chronic Pain market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Chronic Pain market.

Report Insights

• Chronic Pain Patient Population Forecast
• Chronic Pain Market Opportunity (Current and Forecasted)
• Chronic Pain Pipeline Analysis
• Chronic Pain Market Size and Trends
• Chronic Pain Market Opportunity (Current and Forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year Forecast
• Chronic Pain Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Chronic Pain Treatment Addressable Market (TAM)
• Chronic Pain Competitive Landscape
• Chronic Pain Major Companies Insights
• Chronic Pain Price Trends and Analogue Assessment
• Chronic Pain Therapies and Drug Adoption/Uptake
• Chronic Pain Therapies Peak Patient Share Analysis

Report Assessment

• Chronic Pain Current Treatment Practices
• Chronic Pain Unmet Needs
• Chronic Pain Clinical Development Analysis
• Chronic Pain Emerging Drugs Product Profiles
• Chronic Pain Market Attractiveness
• Chronic Pain Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the Chronic Pain market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Chronic Pain?
• What are the disease risks, burdens, and unmet needs of Chronic Pain? What will be the growth opportunities across the 7MM concerning the patient population with Chronic Pain?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Chronic Pain? What are the current guidelines for treating Chronic Pain in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Chronic Pain market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.